Learn More
Imatinib, a targeted inhibitor of the tyrosine kinase activity of the BCR-ABL oncoprotein, has demonstrated considerable efficacy in all phases of chronic myeloid leukemia (CML). Recently, Palandri(More)
LBA6501 Background: MF, a myeloproliferative neoplasm characterized by dysregulation of the JAK pathway, is associated with splenomegaly, constitutional symptoms and reduced lifespan. Ruxolitinib is(More)
This is the first randomized, open-label, multicenter trial designed and powered to directly compare the hemoglobin (Hb) response to epoetin alfa (EPO), 40,000 U once weekly (QW), with that to(More)
PURPOSE We performed a pilot phase II study to evaluate the potential for delivery of rapidly sequenced high-dose chemotherapy treatments rescued with autologous peripheral-blood progenitor cells(More)
8153 Background: Epoetin alfa (EPO) and darbepoetin alfa (DARB) both decrease transfusion requirements and increase hemoglobin (Hb) in anemic cancer patients (pts) receiving chemotherapy (CT). (More)